A Pilot Clinical Trial With Tocotrienol on Breast Cancer (BC)
Effectiveness of Tocotrienol-rich Fraction Combined With Tamoxifen in the Management of Women With Early Breast Cancer: A Pilot Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Selangor
-
Kajang, Selangor, Malaysia, 43000
- Malaysian Palm Oil Board
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- women with estrogen receptor positive tumors.
- 40-60 years of age at the start of the tamoxifen therapy.
- histologically confirmed primary breast cancer.
- a tumor that was positive for estrogen receptors, progesterone receptors, or both.
- an Eastern Cooperative Oncology Group performance status of 0,1, or 2 (scored on a scale of 0 to 5, with lower scores indicating better function).
Exclusion criteria:
- concurrent use of investigational drugs and estrogen receptor status negative or unknown.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Tocotrienol Rich Fraction plus Tamoxifen
|
Tocotrienol Rich Fraction (200mg), daily for five years
Other Names:
|
|
Active Comparator: Placebo plus tamoxifen
|
20mg tamoxifen daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
breast cancer specific survival
Time Frame: Five Years
|
defined as the time from minimization to death due to breast cancer
|
Five Years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
disease free survival
Time Frame: Five years
|
Five years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kalanithi Nesaretnam, PhD, Malaysia Palm Oil Board
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protective Agents
- Micronutrients
- Hormone Antagonists
- Vitamins
- Bone Density Conservation Agents
- Estrogen Antagonists
- Antioxidants
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Vitamin E
- Tocopherols
- Tamoxifen
- Tocotrienols
Other Study ID Numbers
Other Study ID Numbers
- CT369
- 5399 S1 (Registry Identifier: National Medical Research Register,Malaysia)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.